FR3099160B1 - Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant - Google Patents

Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant Download PDF

Info

Publication number
FR3099160B1
FR3099160B1 FR1908344A FR1908344A FR3099160B1 FR 3099160 B1 FR3099160 B1 FR 3099160B1 FR 1908344 A FR1908344 A FR 1908344A FR 1908344 A FR1908344 A FR 1908344A FR 3099160 B1 FR3099160 B1 FR 3099160B1
Authority
FR
France
Prior art keywords
directed against
depseudomonas
aeruginosa
medicine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1908344A
Other languages
English (en)
Other versions
FR3099160A1 (fr
Inventor
Jean-Luc Lenormand
Landry Gayet
Géraldine Mayeux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Polytechnique de Grenoble
Universite Grenoble Alpes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Polytechnique de Grenoble
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1908344A priority Critical patent/FR3099160B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Polytechnique de Grenoble, Universite Grenoble Alpes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2022504553A priority patent/JP2022542883A/ja
Priority to PCT/EP2020/070725 priority patent/WO2021013904A1/fr
Priority to US17/629,161 priority patent/US20220267417A1/en
Priority to EP20742744.4A priority patent/EP4003406A1/fr
Priority to CN202080065451.7A priority patent/CN114651009A/zh
Priority to CA3144663A priority patent/CA3144663A1/fr
Publication of FR3099160A1 publication Critical patent/FR3099160A1/fr
Priority to IL289998A priority patent/IL289998A/en
Application granted granted Critical
Publication of FR3099160B1 publication Critical patent/FR3099160B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L’invention concerne un anticorps monoclonal dirigé contre la protéine OprF de Pseudomonas aeruginosa ou un fragment fonctionnel de cet anticorps. Cet anticorps ou fragment d’anticorps est particulièrement utile pour le traitement préventif ou curatif des infections à Pseudomonas aeruginosa.
FR1908344A 2019-07-23 2019-07-23 Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant Active FR3099160B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1908344A FR3099160B1 (fr) 2019-07-23 2019-07-23 Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
PCT/EP2020/070725 WO2021013904A1 (fr) 2019-07-23 2020-07-22 Anticorps dirigé contre la protéine oprf de pseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
US17/629,161 US20220267417A1 (en) 2019-07-23 2020-07-22 Antibody against the oprf protein of pseudomonas aeruginosa, use thereof as a medicament and pharmaceutical composition containing same
EP20742744.4A EP4003406A1 (fr) 2019-07-23 2020-07-22 Anticorps dirigé contre la protéine oprf de pseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
JP2022504553A JP2022542883A (ja) 2019-07-23 2020-07-22 緑膿菌のＯｐｒＦタンパク質に対する抗体、薬剤としてのその使用、及び前記抗体を含む医薬組成物
CN202080065451.7A CN114651009A (zh) 2019-07-23 2020-07-22 针对铜绿假单胞菌OprF蛋白的抗体、其作为药物的用途和含有该抗体的药物组合物
CA3144663A CA3144663A1 (fr) 2019-07-23 2020-07-22 Anticorps dirige contre la proteine oprf de pseudomonas aeruginosa son utilisation en tant que medicament et composition pharmaceutique le contenant
IL289998A IL289998A (en) 2019-07-23 2022-01-20 Antibody against the oprf protein of Pseudomonas aeruginosa, its use as a medicine and a pharmaceutical preparation containing it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1908344A FR3099160B1 (fr) 2019-07-23 2019-07-23 Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
FR1908344 2019-07-23

Publications (2)

Publication Number Publication Date
FR3099160A1 FR3099160A1 (fr) 2021-01-29
FR3099160B1 true FR3099160B1 (fr) 2022-05-06

Family

ID=69104532

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1908344A Active FR3099160B1 (fr) 2019-07-23 2019-07-23 Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant

Country Status (8)

Country Link
US (1) US20220267417A1 (fr)
EP (1) EP4003406A1 (fr)
JP (1) JP2022542883A (fr)
CN (1) CN114651009A (fr)
CA (1) CA3144663A1 (fr)
FR (1) FR3099160B1 (fr)
IL (1) IL289998A (fr)
WO (1) WO2021013904A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024636A1 (fr) * 1992-05-29 1993-12-09 The University Of British Columbia Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes
EP1961427A3 (fr) * 2002-08-02 2009-11-04 GlaxoSmithKline Biologicals S.A. Vaccin antineisseria comprenant une combinaison d'antigenes
CN101830982A (zh) * 2010-05-27 2010-09-15 王燕 抗铜绿假单胞菌外膜蛋白单克隆抗体的制备方法
JP5893640B2 (ja) * 2010-12-23 2016-03-23 ファルネファ オーストリア ゲーエムベーハー Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用
CA2959165A1 (fr) * 2014-08-29 2016-03-03 Sorrento Therapeutics, Inc. Anticorps therapeutiques qui se lient a oprf et oprl

Also Published As

Publication number Publication date
CA3144663A1 (fr) 2021-01-28
EP4003406A1 (fr) 2022-06-01
FR3099160A1 (fr) 2021-01-29
IL289998A (en) 2022-03-01
JP2022542883A (ja) 2022-10-07
US20220267417A1 (en) 2022-08-25
WO2021013904A8 (fr) 2021-09-23
CN114651009A (zh) 2022-06-21
WO2021013904A1 (fr) 2021-01-28

Similar Documents

Publication Publication Date Title
MA46731A (fr) Anticorps anti-tmprss2 et fragments de liaison à l'antigène
Ferreira et al. SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
BR0211953A (pt) Inibidores de rota complementar ligando-se a cs e csa sem prevenção da formação de csb
MA30382B1 (fr) Anticorps monoclonaux humanises contre le facteur de croissance des hepatocytes
CL2022002670A1 (es) Anticuerpos contra amiloide-bcon piroglutamato y usos de estos (divisional solicitud 202102473).
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Koro et al. Carbamylation of immunoglobulin abrogates activation of the classical complement pathway
PE20211708A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
Rosbjerg et al. Masp-1 and masp-3 bind directly to aspergillus fumigatus and promote complement activation and phagocytosis
CO2022002627A2 (es) Composiciones biofarmacéuticas y procedimientos conexos
Khorattanakulchai et al. Binding of PmClipSP2 to microbial cell wall components and activation of the proPO-activating system in the black tiger shrimp Penaeus monodon
PH12020500205A1 (en) Anti-cd147 antibody
EA202192488A1 (ru) Антитела против tsg-6 и их применения
Sharapova et al. Autoantibodies from SLE patients induce programmed cell death in murine fibroblast cells through interaction with TNFR1 receptor
FR3099160B1 (fr) Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
BR112023019546A2 (pt) Anticorpos anti-tau e usos dos mesmos
Gunter et al. Identification and characterization of the Trypanosoma cruzi B-cell superantigen Tc24

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210129

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

CL Concession to grant licences

Name of requester: SATT LINKSIUM GRENOBLE ALPES, FR

Effective date: 20230130

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6